Tuan Ha-Ngoc

Tuan Ha-Ngoc

President and CEO
AVEO Oncology

Tuan Ha-Ngoc has served as President and Chief Executive Officer since the Company’s inception in 2002. AVEO Oncology is a late-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals and Schering-Plough. The company's lead product, AV-951, a potential best-in-class triple VEGF receptor inhibitor, is completing a Phase 2 clinical trial in more than 200 patients with metastatic renal cell cancer and is expected to enter Phase 3 development in 2009.

Mr. Ha-Ngoc brings over 30 years of pharmaceutical and healthcare leadership experience to AVEO. Before starting AVEO, Mr. Ha-Ngoc co-founded deNovis, Inc., an enterprise-scale software development company focused on automating administrative functions in healthcare. Mr. Ha-Ngoc led deNovis as President and CEO from 1999 until 2002.

From 1998 to 1999, Mr. Ha-Ngoc was Wyeth's Corporate Vice President of Strategic Development. His tenure there followed Wyeth's acquisition of Genetics Institute, where Mr. Ha-Ngoc was Executive Vice President with responsibility for Corporate Development, Commercial Operations, as well as European and Japanese Operations and in addition at various times Legal Affairs, Regulatory, a major R&D program and Program Management. Prior to joining Genetics Institute in 1984, he held various marketing and business positions at Baxter Healthcare, Inc. He started his career in the pharmaceutical industry in 1974 with Sanofi.

Mr. Ha-Ngoc earned an MBA from INSEAD and a Master's in Pharmacy from the University of Paris, France. He serves on the Board of Directors of Human Genome Sciences, Inc. and on the boards of a number of academic and nonprofit organizations, including the Harvard School of Dental Medicine, the Tufts School of Medicine, the Boston Philharmonic Orchestra, the International Institute of Boston and Harvard Medical School's Biomedical Science Careers Program. Mr. Ha-Ngoc is the recipient of the 2007 Ernst & Young New England Entrepreneur of the Year.